AU2017227534A1 - Combination therapy for treatment of ovarian cancer - Google Patents
Combination therapy for treatment of ovarian cancer Download PDFInfo
- Publication number
- AU2017227534A1 AU2017227534A1 AU2017227534A AU2017227534A AU2017227534A1 AU 2017227534 A1 AU2017227534 A1 AU 2017227534A1 AU 2017227534 A AU2017227534 A AU 2017227534A AU 2017227534 A AU2017227534 A AU 2017227534A AU 2017227534 A1 AU2017227534 A1 AU 2017227534A1
- Authority
- AU
- Australia
- Prior art keywords
- inhibitor
- dna
- repair
- damaging
- ovarian cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/156—Polymorphic or mutational markers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Zoology (AREA)
- Immunology (AREA)
- Pathology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Plant Substances (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2023200554A AU2023200554A1 (en) | 2016-02-29 | 2023-02-03 | Combination therapy for treatment of ovarian cancer |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662301225P | 2016-02-29 | 2016-02-29 | |
| US62/301,225 | 2016-02-29 | ||
| PCT/US2017/019843 WO2017151554A1 (en) | 2016-02-29 | 2017-02-28 | Combination therapy for treatment of ovarian cancer |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023200554A Division AU2023200554A1 (en) | 2016-02-29 | 2023-02-03 | Combination therapy for treatment of ovarian cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017227534A1 true AU2017227534A1 (en) | 2018-08-30 |
Family
ID=59744380
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017227534A Abandoned AU2017227534A1 (en) | 2016-02-29 | 2017-02-28 | Combination therapy for treatment of ovarian cancer |
| AU2023200554A Abandoned AU2023200554A1 (en) | 2016-02-29 | 2023-02-03 | Combination therapy for treatment of ovarian cancer |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2023200554A Abandoned AU2023200554A1 (en) | 2016-02-29 | 2023-02-03 | Combination therapy for treatment of ovarian cancer |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US11154538B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3423048A4 (cg-RX-API-DMAC7.html) |
| JP (3) | JP2019508429A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108697666A (cg-RX-API-DMAC7.html) |
| AU (2) | AU2017227534A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3014680A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL261195B (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018010223A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017151554A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20240136T1 (hr) | 2016-06-29 | 2024-04-12 | Tesaro, Inc. | Metode liječenja raka jajnika |
| KR20200106053A (ko) * | 2017-12-29 | 2020-09-10 | 버텍스 파마슈티칼스 인코포레이티드 | Atr 억제제를 사용한 암 치료 방법 |
| JP2021510702A (ja) | 2018-01-12 | 2021-04-30 | プロリンクス エルエルシー | 相乗的がん治療 |
| EP3966782A2 (en) | 2019-05-06 | 2022-03-16 | Tesaro, Inc. | Methods for characterizing and treating a cancer type using cancer images |
| CN113462784B (zh) * | 2021-08-31 | 2021-12-10 | 迈杰转化医学研究(苏州)有限公司 | 一种构建用于同源重组修复缺陷检测的靶标集合的方法 |
| JPWO2023157891A1 (cg-RX-API-DMAC7.html) | 2022-02-16 | 2023-08-24 | ||
| WO2024111564A1 (ja) * | 2022-11-21 | 2024-05-30 | 富士フイルム株式会社 | トポテカン又はその塩を内包するリポソーム組成物およびdna損傷修復阻害剤を含む組合せ医薬 |
| CN116024162B (zh) * | 2023-02-27 | 2025-01-10 | 山东大学 | Egcg联合chk2抑制剂在改善卵成熟或胚胎发育中的应用 |
| TW202502354A (zh) * | 2023-06-02 | 2025-01-16 | 美商薩諾管理公司 | 同源重組修復缺陷(hrd)作為預測性生物標記以便使用wee1抑制劑治療癌症 |
| CN117860753A (zh) * | 2023-11-30 | 2024-04-12 | 华中科技大学 | 一种cdc7抑制剂化合物xl413在制备预防或治疗肝损伤和肝纤维化药物及应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2594874T3 (es) | 2004-11-18 | 2016-12-23 | Synta Pharmaceuticals Corp. | Compuestos de triazol que modulan la actividad de HSP90 |
| AU2008321382A1 (en) | 2007-11-12 | 2009-05-22 | Bipar Sciences, Inc. | Treatment of uterine cancer and ovarian cancer with a PARP inhibitor alone or in combination with anti-tumor agents |
| EP2714038A1 (en) * | 2011-05-24 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with mtor/pi3k inhibitors |
| EP2714033A1 (en) * | 2011-05-26 | 2014-04-09 | Synta Pharmaceuticals Corp. | Combination therapy of hsp90 inhibitory compounds with chk inhibitors |
| WO2013067162A1 (en) * | 2011-11-02 | 2013-05-10 | Synta Pharmaceuticals Corp. | Cancer therapy using a combination of hsp90 inhibitors with topoisomerase i inhibitors |
| WO2014138101A1 (en) | 2013-03-04 | 2014-09-12 | Board Of Regents, The University Of Texas System | Gene signature to predict homologous recombination (hr) deficient cancer |
| JP6114075B2 (ja) * | 2013-03-07 | 2017-04-12 | 三菱航空機株式会社 | 航空機の警報システム、及び、航空機 |
| US20160120848A1 (en) * | 2013-05-21 | 2016-05-05 | Synta Pharmaceuticals Corp. | Specific cancer treatment regimes with ganetespib |
| DK3686288T3 (da) | 2014-08-15 | 2023-05-22 | Myriad Genetics Inc | Fremgangsmåder og materialer til analyse af homolog rekombinationsdeficiens |
-
2017
- 2017-02-28 US US16/080,752 patent/US11154538B2/en not_active Expired - Fee Related
- 2017-02-28 CA CA3014680A patent/CA3014680A1/en active Pending
- 2017-02-28 JP JP2018545198A patent/JP2019508429A/ja active Pending
- 2017-02-28 WO PCT/US2017/019843 patent/WO2017151554A1/en not_active Ceased
- 2017-02-28 EP EP17760573.0A patent/EP3423048A4/en not_active Withdrawn
- 2017-02-28 AU AU2017227534A patent/AU2017227534A1/en not_active Abandoned
- 2017-02-28 CN CN201780013983.4A patent/CN108697666A/zh active Pending
- 2017-02-28 MX MX2018010223A patent/MX2018010223A/es unknown
-
2018
- 2018-08-16 IL IL261195A patent/IL261195B/en unknown
-
2022
- 2022-03-29 JP JP2022053212A patent/JP2022079569A/ja not_active Withdrawn
-
2023
- 2023-02-03 AU AU2023200554A patent/AU2023200554A1/en not_active Abandoned
-
2024
- 2024-02-13 JP JP2024019509A patent/JP2024054312A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2024054312A (ja) | 2024-04-16 |
| MX2018010223A (es) | 2018-11-09 |
| US11154538B2 (en) | 2021-10-26 |
| CN108697666A (zh) | 2018-10-23 |
| CA3014680A1 (en) | 2017-09-08 |
| WO2017151554A1 (en) | 2017-09-08 |
| US20190060285A1 (en) | 2019-02-28 |
| AU2023200554A1 (en) | 2023-03-02 |
| IL261195B (en) | 2022-06-01 |
| JP2019508429A (ja) | 2019-03-28 |
| EP3423048A1 (en) | 2019-01-09 |
| JP2022079569A (ja) | 2022-05-26 |
| IL261195A (en) | 2018-10-31 |
| EP3423048A4 (en) | 2019-10-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US11154538B2 (en) | Combination therapy for treatment of ovarian cancer | |
| Fu et al. | BRCA1 and breast cancer: molecular mechanisms and therapeutic strategies | |
| US20220175752A1 (en) | Methods of Treating Ovarian Cancer | |
| US10851425B2 (en) | Method for treating cancer | |
| Begg et al. | Strategies to improve radiotherapy with targeted drugs | |
| Lee et al. | PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies | |
| Xu et al. | Prediction of copper transport protein 1 (CTR1) genotype on severe cisplatin induced toxicity in non-small cell lung cancer (NSCLC) patients | |
| US11028448B2 (en) | Methods of identifying risk of vascular endothelial growth factor (VEGF) pathway inhibitor-induced hypertension | |
| Tufail | DNA repair pathways in breast cancer: from mechanisms to clinical applications | |
| Wu et al. | Studies of lncRNAs in DNA double strand break repair: what is new? | |
| US20180209956A1 (en) | HTS Assay for Identifying Small Molecule Inhibitors of RAD52 and Uses of Identified Small Molecule Inhibitors for Treatment and Prevention of BRCA-Deficient Malignancies | |
| Chatterjee et al. | Unveiling the vulnerabilities of synthetic lethality in triple-negative breast cancer | |
| WO2021011609A1 (en) | Methods of treating ovarian, fallopian tube and peritoneal cancer | |
| WO2011085288A2 (en) | Method of administration and treatment | |
| Yoon et al. | Open-label, single-arm, phase 2 trial to investigate the efficacy of sitravatinib plus tislelizumab combination as a second-line treatment for advanced biliary tract cancer | |
| Tyszka et al. | Niraparib maintenance in newly diagnosed advanced ovarian cancer—review and case series | |
| EP4686475A1 (en) | Xpg inhibitors for use in the treatment of cancer | |
| Jackson | The DNA Damage Checkpoint | |
| CA3036568C (en) | Methods for treating ovarian cancer | |
| Treré et al. | Ribosome biogenesis rate, a parameter of sensitivity to chemotherapeutic drugs inhibiting rRNA synthesis | |
| WO2025109076A1 (en) | Biomarkers for identifying patients having tumors with homologous recombination deficiency | |
| TW202131925A (zh) | 治療癌症之方法 | |
| Chau | Landscape of Molecular Alterations of Three Rare Subtypes of Non-small Cell Lung Cancer | |
| WO2024243078A1 (en) | Hsp90 inhibitors for the treatment of cancer | |
| TW202610631A (zh) | 用於以2,2'-二硫基雙乙烷磺化物、卡鉑及吡咯葉酸治療非小細胞肺癌的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |